B. Breve Probiotic Modulation of the IL-23/Th17 Axis in Psoriasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psoriasis are ineffective in completely curing the condition, which is prone to recurrence and often associated with significant side effects, and there is a need for a cost-effective method to inhibit the IL-23/Th17 axis-related inflammatory factors.
Innovation Solution
The use of Bifidobacterium breve CCFM1078 strain to inhibit the release of IL-23/Th17 axis-related inflammatory factors, reducing IL-23, IL-22, and IL-17 levels in the skin, thereby preventing and alleviating psoriasis symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If biological agents targeting the IL-23/Th17 axis are used to treat psoriasis, then treatment efficacy is improved, but cost increases significantly
Solution Approach 1:
The patent replaces expensive biological agents with probiotics (Bifidobacterium breve CCFM1078), which are low-cost microorganisms that can be administered orally. The probiotic serves as a disposable, affordable alternative to costly biologics while achieving comparable therapeutic effects through modulation of the IL-23/Th17 axis.
Solution Approach 2:
The patent introduces probiotics as an intermediary substance that indirectly modulates the immune system by affecting gut microbiota composition and function. This intermediary approach allows treatment of psoriasis without directly administering expensive biological agents, thereby reducing cost while maintaining efficacy.
2Quantity of substance
If conventional treatment regimens are used for psoriasis, then cost is reduced, but treatment efficacy deteriorates
Solution Approach 1:
The patent changes the therapeutic parameter from conventional low-cost treatments (topical corticosteroids, traditional systemics) to probiotic-based therapy. This parameter change enables cost-effective treatment while achieving improved efficacy through the probiotic's ability to modulate immune responses via the gut-skin axis.
3Object-generated harmful factors
If psoriasis is treated with existing methods, then some symptom relief is achieved, but recurrence rate remains high
Solution Approach 1:
The patent employs probiotics that colonize the gut and continuously modulate immune responses, enabling the body's own immune system to regulate psoriasis pathology. This self-service mechanism provides sustained symptom relief and reduces recurrence by establishing long-term immune balance rather than temporary suppression.
Solution Approach 2:
The probiotic treatment provides continuous therapeutic action through ongoing colonization and metabolism of Bifidobacterium breve CCFM1078 in the gut. This continuous presence ensures sustained modulation of the IL-23/Th17 axis, preventing symptom relapse and reducing recurrence rates compared to intermittent conventional treatments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
B. breve CCFM1078 effectively reduces IL-23, IL-22, and IL-17 levels by 20.3%, 22.0%, and 18.3% respectively, improving skin conditions and inhibiting skin cuticle thickening in psoriasis-like mice, offering a promising alternative to existing treatments.
Implementation Method 1
The B. breve CCFM1078 effectively improves skin conditions by inhibiting skin thickening and reducing IL-23, IL-22, and IL-17 levels by 20.3%, 22.0%, and 18.3% respectively
Data Source
AI summary
The disclosure discloses a strain of Bifidobacterium breve capable of preventing and relieving psoriasis and application thereof, belonging to the field of microbial technologies and medical technologies. The disclosure provides new uses of B. breve CCFM1078 in inhibiting the release of IL-23/Th17 axis related inflammatory factors, and relieving the psoriasis. The B. breve CCFM1078 of the disclosure can relieve the lesion skin of psoriasis-like mice, and can inhibit thickening of the skin epidermal layer, so that the IL-23 level, the IL-22 level and the IL-17 level in the skin decrease by 20.3%, 22.0% and 18.3%, respectively. The B. breve CCFM1078 has a great application prospect in the preparation of a product (such as a food, a drug or a health food) for preventing and/or treating psoriasis.